Biocaptiva Secures £1.58M, Unveils Pioneering Liquid Biopsy Tech in US
March 10, 2026, 9:37 am
Biocaptiva, an Edinburgh biotech firm, secured £1.58M in new funding. They launched their innovative msX magnetic bead technology in the US. This platform extracts cell-free DNA directly from whole blood. It eliminates traditional liquid biopsy bottlenecks. The technology simplifies and speeds up cancer research and diagnostics. Funds support R&D expansion and product development. Alan Schafer, an industry veteran, joined as CTO. Biocaptiva revolutionizes non-invasive genetic testing. It aims for faster, better cancer insights and improved global patient outcomes. This positions Biocaptiva as a leader in precision oncology, driving forward diagnostic capabilities and research acceleration for a healthier future.
Biocaptiva, an innovative biotech company, has achieved a significant milestone. The Edinburgh-based firm secured £1.58 million in new funding. This capital injection fuels its strategic growth. Simultaneously, Biocaptiva launched its flagship msX platform in the United States. This marks a pivotal moment for cancer research and diagnostics.
The funding round saw strong support. Existing investors Archangels led the initiative. Old College Capital, BBI, and Scottish Enterprise also contributed. New investor EverQuest Capital Partners joined the syndicate. This collective backing underscores confidence in Biocaptiva's technology and vision.
Biocaptiva specializes in liquid biopsy technology. Its focus lies in overcoming critical limitations. Traditional blood samples yield low concentrations of cell-free DNA (cfDNA). This poses a major hurdle for current cancer diagnostics. The msX platform directly addresses this challenge.
The company's patented msX platform is a game-changer. It leverages novel magnetic bead technology. This system extracts DNA directly from whole blood. Critically, it does so without centrifuges. It also requires no additional reagents. This simplifies the entire process.
Current liquid biopsy methods face a bottleneck. Sample preparation is often complex and time-consuming. Biocaptiva’s msX platform offers a streamlined alternative. It delivers higher-quality samples. Processing is faster and simpler. This advancement has profound implications.
The msX platform revolutionizes sample collection. It enables larger samples. Extraction is faster. Processing is simpler. Capabilities are fully automatable. This translates to accelerated cancer research. It promises deeper insights. Millions globally could see improved outcomes. The technology makes liquid biopsy testing more reliable. It enhances scalability and accessibility.
Cancer research will benefit immensely. Researchers can now obtain superior samples. They can do so with unprecedented ease. This accelerates the pace of discovery. It streamlines the development of new diagnostics. The potential for personalized medicine expands significantly.
The funding will support key initiatives. A substantial portion is allocated to research and development. Biocaptiva plans to expand its product range. It will explore new applications for its technology. This ensures continuous innovation.
Further bolstering its leadership, Biocaptiva appointed Alan Schafer as Chief Technology Officer. Schafer brings extensive expertise. He possesses over 30 years of experience. His background spans genetics technologies and molecular diagnostics. Schafer previously served as CTO at Inivata. He was CEO at Population Genetics Technologies and 14M Genomics. His experience also includes a role as VP Technology Development (Global) at GlaxoSmithKline. His addition strengthens Biocaptiva's technical leadership. It signals a commitment to advanced innovation.
The launch of msX kits in Boston is strategic. It targets the vital US market. The initial focus is on research use. This aims to build a robust body of evidence. It will demonstrate the technology’s effectiveness across diverse applications. The US represents a massive market for non-invasive genetic testing.
Biocaptiva's entry into the US market is well-timed. The market for non-invasive genetic testing is growing rapidly. Demand for advanced diagnostic tools is high. The msX platform is positioned to capture a significant share. Its unique advantages offer a competitive edge.
The company's origins trace back to 2021. It spun out from the University of Edinburgh. This academic lineage underpins its scientific rigor. CEO Jeremy Wheeler leads Biocaptiva. His leadership drives the company’s mission. That mission is to transform cancer diagnostics.
Biocaptiva stands at a pivotal growth point. The msX beads launch marks this. The technology boasts remarkable market potential. It addresses a long-standing bottleneck in liquid biopsy sample preparation. This market is expanding. The company aims to lead this expansion.
Scottish Enterprise’s investment underscores its commitment. It boosts capital investment in Scottish businesses. This supports the economy. It drives productivity. It creates higher-value jobs. This demonstrates the broader economic impact of Biocaptiva's success.
The implications for precision oncology are vast. The ability to collect high-quality cfDNA samples is crucial. It supports early detection. It guides treatment selection. It monitors disease progression. Biocaptiva’s technology enhances all these areas.
This innovation promises better health outcomes. It empowers scientists. It equips clinicians. They gain superior tools for understanding cancer. This accelerates the path toward more effective therapies. It brings hope to millions worldwide.
Biocaptiva’s funding and US launch are significant milestones. They underscore the company's trajectory. Its magnetic bead technology reshapes liquid biopsy. It simplifies complex processes. It drives scientific progress. Biocaptiva is setting new standards in cancer diagnostics. Its journey will impact global health.
Biocaptiva, an innovative biotech company, has achieved a significant milestone. The Edinburgh-based firm secured £1.58 million in new funding. This capital injection fuels its strategic growth. Simultaneously, Biocaptiva launched its flagship msX platform in the United States. This marks a pivotal moment for cancer research and diagnostics.
The funding round saw strong support. Existing investors Archangels led the initiative. Old College Capital, BBI, and Scottish Enterprise also contributed. New investor EverQuest Capital Partners joined the syndicate. This collective backing underscores confidence in Biocaptiva's technology and vision.
Biocaptiva specializes in liquid biopsy technology. Its focus lies in overcoming critical limitations. Traditional blood samples yield low concentrations of cell-free DNA (cfDNA). This poses a major hurdle for current cancer diagnostics. The msX platform directly addresses this challenge.
The company's patented msX platform is a game-changer. It leverages novel magnetic bead technology. This system extracts DNA directly from whole blood. Critically, it does so without centrifuges. It also requires no additional reagents. This simplifies the entire process.
Current liquid biopsy methods face a bottleneck. Sample preparation is often complex and time-consuming. Biocaptiva’s msX platform offers a streamlined alternative. It delivers higher-quality samples. Processing is faster and simpler. This advancement has profound implications.
The msX platform revolutionizes sample collection. It enables larger samples. Extraction is faster. Processing is simpler. Capabilities are fully automatable. This translates to accelerated cancer research. It promises deeper insights. Millions globally could see improved outcomes. The technology makes liquid biopsy testing more reliable. It enhances scalability and accessibility.
Cancer research will benefit immensely. Researchers can now obtain superior samples. They can do so with unprecedented ease. This accelerates the pace of discovery. It streamlines the development of new diagnostics. The potential for personalized medicine expands significantly.
The funding will support key initiatives. A substantial portion is allocated to research and development. Biocaptiva plans to expand its product range. It will explore new applications for its technology. This ensures continuous innovation.
Further bolstering its leadership, Biocaptiva appointed Alan Schafer as Chief Technology Officer. Schafer brings extensive expertise. He possesses over 30 years of experience. His background spans genetics technologies and molecular diagnostics. Schafer previously served as CTO at Inivata. He was CEO at Population Genetics Technologies and 14M Genomics. His experience also includes a role as VP Technology Development (Global) at GlaxoSmithKline. His addition strengthens Biocaptiva's technical leadership. It signals a commitment to advanced innovation.
The launch of msX kits in Boston is strategic. It targets the vital US market. The initial focus is on research use. This aims to build a robust body of evidence. It will demonstrate the technology’s effectiveness across diverse applications. The US represents a massive market for non-invasive genetic testing.
Biocaptiva's entry into the US market is well-timed. The market for non-invasive genetic testing is growing rapidly. Demand for advanced diagnostic tools is high. The msX platform is positioned to capture a significant share. Its unique advantages offer a competitive edge.
The company's origins trace back to 2021. It spun out from the University of Edinburgh. This academic lineage underpins its scientific rigor. CEO Jeremy Wheeler leads Biocaptiva. His leadership drives the company’s mission. That mission is to transform cancer diagnostics.
Biocaptiva stands at a pivotal growth point. The msX beads launch marks this. The technology boasts remarkable market potential. It addresses a long-standing bottleneck in liquid biopsy sample preparation. This market is expanding. The company aims to lead this expansion.
Scottish Enterprise’s investment underscores its commitment. It boosts capital investment in Scottish businesses. This supports the economy. It drives productivity. It creates higher-value jobs. This demonstrates the broader economic impact of Biocaptiva's success.
The implications for precision oncology are vast. The ability to collect high-quality cfDNA samples is crucial. It supports early detection. It guides treatment selection. It monitors disease progression. Biocaptiva’s technology enhances all these areas.
This innovation promises better health outcomes. It empowers scientists. It equips clinicians. They gain superior tools for understanding cancer. This accelerates the path toward more effective therapies. It brings hope to millions worldwide.
Biocaptiva’s funding and US launch are significant milestones. They underscore the company's trajectory. Its magnetic bead technology reshapes liquid biopsy. It simplifies complex processes. It drives scientific progress. Biocaptiva is setting new standards in cancer diagnostics. Its journey will impact global health.